Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Metlife (MET-PF) Cash & Equivalents (2016 - 2025)

Metlife has reported Cash & Equivalents over the past 17 years, most recently at $11.5 billion for Q4 2025.

  • Quarterly results put Cash & Equivalents at $11.5 billion for Q4 2025, down 3.36% from a year ago — trailing twelve months through Dec 2025 was $11.5 billion (down 3.36% YoY), and the annual figure for FY2025 was $11.5 billion, down 3.36%.
  • Cash & Equivalents for Q4 2025 was $11.5 billion at Metlife, up from $9.7 billion in the prior quarter.
  • Over the last five years, Cash & Equivalents for MET-PF hit a ceiling of $25.0 billion in Q2 2021 and a floor of $1.3 billion in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $11.4 billion (2025), compared with a mean of $12.2 billion.
  • Peak annual rise in Cash & Equivalents hit 344.67% in 2021, while the deepest fall reached 65.58% in 2021.
  • Metlife's Cash & Equivalents stood at $2.0 billion in 2021, then tumbled by 34.22% to $1.3 billion in 2022, then skyrocketed by 134.19% to $3.0 billion in 2023, then surged by 293.91% to $11.9 billion in 2024, then decreased by 3.36% to $11.5 billion in 2025.
  • The last three reported values for Cash & Equivalents were $11.5 billion (Q4 2025), $9.7 billion (Q3 2025), and $22.2 billion (Q2 2025) per Business Quant data.